|
|
|
|
|
|
|
|
|
05.12.25 - 11:12
|
Takeda and Innovent fulfil close conditions for ADC and IO therapies (PBR)
|
|
|
In October 2025, the two companies signed the deal as part of their focus on bispecifics and ADCs. The agreement aims to expedite the worldwide development and commercialisation
The post Takeda and Innovent fulfil close conditions for ADC and IO therapies appeared first on Pharmaceutical Business review....
|
|
|
05.12.25 - 03:15
|
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net (AAStocks)
|
|
|
In October 2025, INNOVENT BIO (01801.HK) announced a global strategic partnership with Takeda Pharmaceutical (4502.JP). This partnership involves a licensing agreement valued at USD11.4 billion and a USD100 million strategic equity investment from Takeda.INNOVENT BIO announced that all conditions precedent to each of the license......
|
|
|
|
|
|
|
03.12.25 - 16:36
|
insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors (Business Wire)
|
|
|
Former Takeda CSO and a16z Bio + Health Founder to Guide Clinical Translation and Scaling of insitro's ChemML™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of two scientific advisors: Stephen Hitchcock, Ph.D., a preeminent drug development leader and former Chief Scientific Officer of Takeda, and Vijay Pande, Ph.D., co-founder of VZVC and, previously, founder and General Partner of Andreessen Horowitz's Bio + Health fund.
Hitchcock and Pande will advise on the continued development and scaling of insitro's AI-driven ChemML™ platform as it is deployed across insitro's pipeline and partner programs. Their guidance will focus on translating compelling targets into the medicinal chemistry and preclinical development strategies required to advance therapeutics into clinical trials – connecting computational prediction with the realities of drug development at scale.
“Drug discovery often falters ...
|
|
|
|
|
25.11.25 - 17:30
|
Wisner Baum Unleashes RICO to Expose Big Pharma′s Hidden Fraud (PR Newswire)
|
|
|
In a groundbreaking class action, Wisner Baum LLP is invoking the civil RICO statute to hold Takeda and Eli Lilly accountable for allegedly concealing the cancer risks of diabetes drug Actos. The case, now nationally certified, seeks treble damages and sets a precedent for confronting......
|
|
|
|
|
|
|
21.11.25 - 14:06
|
Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index (SCMP)
|
|
|
Innovent Biologics will join the Hang Seng Index next month in the latest quarterly review as the compiler of the city's stock benchmark presses ahead with its plan to increase the number of constituents to 100.
The biotech firm, based in eastern Jiangsu province, has become the only new constituent of the blue-chip indicator, one month after it signed an US$11.4 billion outsourcing deal with Japan's Takeda Pharmaceuticals to co-develop and commercialise three specific investigational cancer......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
